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Influence of Activin A Supplementation
During Human Embryonic Stem Cell Derivation
on Germ Cell Differentiation Potential
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Susana M. Chuva de Sousa Lopes,3,* and Petra De Sutter1,*
Human embryonic stem cells (hESCs) are more similar to ‘‘primed’’ mouse epiblast stem cells (mEpiSCs).
mEpiSCs, which are derived in Activin A, show an increased propensity to form primordial germ cell (PGC)-like
cells in response to bone morphogenic protein 4 (BMP4). Hence, we hypothesized that hESCs derived in the
presence of Activin A may be more competent in differentiating towards PGC-like cells after supplementation
with BMP4 compared to standard hESC lines. We were able to successfully derive two hESC lines in the
presence of Activin A, which were pluripotent and showed higher base levels of STELLA and cKIT compared to
standard hESC lines derived without Activin A addition. Furthermore, upon differentiation as embryoid bodies
in the presence of BMP4, we observed upregulation of VASA at day 7, both at the transcript and protein level
compared to standard hESC lines, which appeared to take longer time for PGC specification. Unlike other hESC
lines, nuclear pSMAD2/3 presence confirmed that Activin signalling was switched on in Activin A-derived
hESC lines. They were also responsive to BMP4 based on nuclear detection of pSMAD1/5/8 and showed
endodermal differentiation as a result of GATA-6 expression. Hence, our results provide novel insights into the
impact of hESC derivation in the presence of Activin A and its subsequent influence on germ cell differentiation
potential in vitro.
Introduction
The first cells appearing in the mammalian germ celllineage are the PGCs, a prerequisite to sustain the con-
tinuation of species from one generation to the next. Upon
spontaneous differentiation of hESCs as embryoid bodies
(EBs), several early PGC markers STELLA (Dppa3), FRAGILIS
(Ifitm3), cKIT (kit), and late PGC marker VASA (Ddx4) have
been detected [1]. Subsequently, several attempts have been
made to develop more efficient protocols for deriving germ
cells in vitro from ESCs. BMP4 was found to play a prominent
role in inducing germ cell gene expression, especially of the
postmigratory germ cell marker VASA in in vitro derived
PGCs from hESCs [2]. Efforts were also made to develop an
efficient step-wise protocol by supplementing hESCs with a
growth factor cocktail in a time-dependent manner mimick-
ing the in vivo environment [3–5]. In addition, it was found
that coculture of hESCs with Sertoli cells or human fetal go-
nadal cells boosted germ cell differentiation [6,7] based on the
expression of early and late germ cell markers. hESCs were
also genetically manipulated by overexpressing DAZL to
induce germ cell differentiation or transfected with VASA-
pEGFP-1 reporter construct to identify and isolate hESC-
derived PGCs in vitro [8,9]. Culture strategies, such as EB
culture, adherent culture, colony size, frequency of refresh-
ment of cultures, are all shown to have an effect on directed
differentiation of hESCs towards PGCs [6,10].
In all the studies undertaken for hESC differentiation to-
wards PGCs, multiple hESC lines were employed. More
evidence suggests that hESC lines differ from each other in
their lineage-specific differentiation potential [11,12]. These
differences between hESC lines may be due to several fac-
tors, such as embryo quality, derivation technique, and in-
herent genetic identity or used culture conditions during
derivation and culture. Therefore, it becomes a necessity to
screen for the ideal hESC line before starting differentiation.
It is also suggested that derivation of hESC lines in condi-
tions specific towards lineage of interest might help yield
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valuable results [11,12]; however, this has not been investi-
gated yet.
The TGFb signaling pathway is composed of two main
branches, namely the TGFb/Activin/Nodal branch involv-
ing SMAD2/3 proteins, which maintain hESC pluripotency,
and the SMAD1/5/8 branch acting downstream of BMP4
and GDF ligands during differentiation [13,14]. Activin A is
one of the important members of the TGFb superfamily. In
situ ligand binding in male Sprague-Dawley rats has shown
the ability of Activin A to bind to germ cells [15]. In juvenile
mice testis, in vivo progression of germ cell maturation was
influenced by Activin A bioactivity during the onset of
spermatogenesis [16]. It was found to be the first Sertoli cell
by-product that was involved in differentiation of male germ
cells in meiotic state [17]. In fetal mouse testis, it keeps a
balance between Sertoli and germ cell proliferation [18]. In
humans, during the onset of primordial follicle formation, it
aids in germ cell proliferation and survival [19] and also
regulates follicle formation and growth in vitro [20]. Re-
cently, Activin A was shown to suppress the retinoic acid
inhibitor CYP26B1 and to help inducing meiosis [21].
It is becoming increasingly clear that hESCs are in fact
similar to mEpiSCs, sharing properties, such as dependence
on TGFb/Activin signaling to maintain their pluripotency
and ability to differentiate into PGC-like cells upon exposure
to BMP4 [22–25]. In connection to this, our group recently
showed that the human ICM outgrowth first undergoes a
transient epiblast-like state before hESCs are established,
which substantiates their primed pluripotency status [26].
mEpiSCs, which are derived in the presence of Activin A
[27], appear to retain characteristics of the original epiblast
and show strong potential to generate PGC-like cells in vitro,
which are able to further develop into late germ cells [24]. In
addition, male and female germ cell specification was in-
duced in mESCs and mouse induced pluripotent stem cells
by culturing them in Activin A to obtain early pregas-
trulating epiblast-like cells (EpiLCs), which gave rise to PGC-
like cells in the presence of BMP4 [28,29].
The results that we present here indicate that hESC deri-
vation in the presence of Activin A has a significant impact
on the state of the derived hESC lines. We showed that ad-
dition of Activin A during hESC derivation induced in-
creased germ cell differentiation potential compared to hESC
lines derived in standard conditions without Activin A.
Materials and Methods
Ethical permission
All patients donating embryos signed informed consents
before their IVF/ICSI cycle. Approval for the current study
was obtained from the Ghent University Hospital Ethical
Committee (2009/281) and from the Belgian Federal Ethical
Committee on Embryo Research (Adv-030).
hESC derivation and culture
To derive our hESC lines in both Activin A and standard
derivation conditions, all human embryos donated for re-
search were randomized and day 6 human blastocysts were
scored according to the grading system of Stephenson and
colleagues [30]. Blastocysts with grade A and B inner cell
mass (large and distinct inner cell mass) [31,32] were exposed
to Acidic Tyrode’s solution (Cat No. T1788; Sigma) to re-
move the zona pellucida, washed in hESC media and plated
on a feeder layer of CD1 mouse embryonic fibroblasts
(MEFs) pretreated with mitomycin-C (Cat No. M4287; Sig-
ma). For standard hESC lines UGent11-5, UGent11-6, and
UGent11-7, culturing from blastocyst to hESC stage was
carried out in a low-oxygen environment at 37C, consisting
of 6% CO2, and 5% O2, using standard hESC medium
composed of Knockout Dulbecco’s Modified Eagle Medium
(KO-DMEM, Cat No. 10829-018; Invitrogen), 20% Knockout
Serum Replacement (KO-SR, Cat No. 10828-028; Invitrogen),
1% nonessential amino acids (NEAA, Cat No. 11140-035;
Invitrogen), 0.1 mM L-glutamine (Cat No. 25030-024; In-
vitrogen), 1% penicillin/streptomycin (Cat No. 15140-122;
Invitrogen), 0.1 mM b-mercaptoethanol (Cat No. 31350-010;
Invitrogen) and 4 ng/mL basic fibroblast growth factor
(bFGF, Cat No. 100-18B; Peprotech). Cultures were refreshed
daily and monitored closely for postinner cell mass-inter-
mediates (PICMIs) [26,33]. Within approximately 7 days,
hESCs outgrowths were cut mechanically, transferred to
freshly inactivated MEFs, and continually mechanically
passaged until several colonies appeared. After this, hESCs
were maintained and split 1:6 onto freshly inactivated MEFs
every 5–6 days using 1 mg/mL collagenase type IV (Cat No.
17104-019; Invitrogen) with daily medium changes to keep
hESCs in an undifferentiated state.
For deriving the hESC lines UGent11-4-ActA and UGent12-
3-ActA, the medium was supplemented with 20 ng/mL Ac-
tivin A (Cat No. 338-AC-010; R&D Systems) from the day 6
blastocyst stage onwards until hESC passage 6. After that, the
lines were further cultured in standard hESC media without
Activin A.
Karyotyping
Early passage hESCs were grown to confluency and ex-
posed to colcemid (1:100 in salt solution, Cat No. 15210-057
Karyomax; Invitrogen) to arrest the cells at metaphase. They
were then treated with 0.25% trypsin-EDTA (Cat No. 25200-
056; Invitrogen) and exposed to hypotonic HCl solution (Cat
No. T-3038; Sigma) followed by fixation in 1:3 methanol/
acetic acid solution (Cat No. 1.06009.1000, Merck; Cat No.
A6283, Sigma). Karyotype analysis was performed for 10
numerical spreads of metaphase and 3 complete karyograms
using G-banding technique as previously described [34].
Alkaline phosphatase live staining
Undifferentiated hESCs were washed twice with DMEM/
F-12 (Cat No. 31331-028; Invitrogen) for 2–3 min. They were
then incubated in 1 · alkaline phosphatase (AP) Live Stain
(Cat No.A14353; Molecular Probes, Life Technology) for
30 min. Next, hESCs were washed twice with DMEM/F-12
for 5 min to remove AP Live Stain. Fresh DMEM/F-12 was
added to fluorescent-labeled hESC cultures and they were
visualized using standard FITC filter by fluorescence mi-
croscopy.
Differentiation of hESCs towards PGCs
Activin A-derived hESC lines (UGent11-4-ActA and
UGent12-3-ActA) were maintained in hESC conditions sim-
ilar to standard hESC lines (UGent11-5, UGent11-6 and
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UGent11-7) after passage 6. All hESC lines were used be-
tween passages 20–25 to maintain homogeneity and to un-
derstand the impact of derivation conditions on PGC
differentiation of hESCs. Also, we performed karyotyping of
all hESC lines before starting our experiments. All hESC lines
were karyotypically normal. Briefly, hESCs were washed
with 1· phosphate buffered saline (PBS), incubated with
collagenase for 6 min and subsequently gently scraped from
the culture flasks with a flattened needle. Collagenase was
neutralized with differentiation medium (80% KO-DMEM,
20% fetal bovine serum, NEAA, L-glutamine, penicillin/
streptomycin and b-mercaptoethanol). hESCs were allowed
to settle by gravity for 15–20 min and were subsequently
resuspended in germ cell differentiation medium consisting
of differentiation medium supplemented with 50 ng/mL
BMP4 (Cat No. 314-BP-010; R&D Systems). Cells were then
transferred onto 24-well Costar Ultra Low Attachment
Clear Flat Bottom plates (Cat No. 3473; Corning) and al-
lowed to differentiate for 3, 7 and 14 days in low-oxygen
conditions. Germ cell differentiation medium was replaced
every alternate day (1 mL per well). For dose-response
studies of BMP4, the hESC line UGent11-4-ActA was dif-
ferentiated as EBs up to day 7 in differentiation medium
containing 10 ng/mL BMP4, 50 ng/mL BMP4, or 100 ng/
mL BMP4.
Immunocytochemistry
EBs and hESCs were fixed in 4% paraformaldehyde in PBS
at 4C and stored in 100% methanol at - 20C and in 1· PBS
at 4C, respectively. EBs were rehydrated through a series of
methanol/water solutions and washed in PBST (PBS + 0.1%
Tween-20) twice for 10 min. Next, they were rinsed in TBST
(Tris-buffered saline + 0.1% TritonX-100, pH 7.4) and blocked
in 0.5%BSA/TBST blocking solution at 4C overnight before
incubation with primary antibody for 2 days at 4C (rotat-
ing). They were washed in TBST five times for 30 min at
room temperature and incubated with secondary antibody
overnight at 4C (rotating). EBs were again washed in TBST
(5 times for 30 min), mounted on glass slides using Vecta-
shield with DAPI (Vector Laboratories Ltd.).
hESCs were rinsed in 1· PBS, permeabilized in 0.1%Tri-
tonX-100/1· PBS for 8 min, then washed in 1· PBS, and
blocked in 0.05% Tween-20/1% BSA/1· PBS blocking so-
lution for 1 h at room temperature. hESCs were then incu-
bated with primary antibody overnight at 4C, washed three
times in 1· PBS, and incubated with secondary antibody for
1 h at room temperature. They were then washed again three
times in 1· PBS and subsequently mounted on glass slides
using Vectashield with DAPI.
Primary antibodies used were goat anti-OCT4 (1:200, SC-
8628; Santa Cruz Biotechnology, Inc.), rabbit anti-NANOG
(1:200, AF1997; R&D Systems), rabbit anti-VASA (1:500,
ab13840, Abcam; 1:500, AF2030; R&D Systems), rabbit anti-
pSMAD2/3 (1:100, No. 9510; Cell Signalling Technologies,
Bioke´), rabbit anti-pSMAD1/5/8 (1:100, No. 9511, Cell Sig-
nalling Technologies, Bioke´). Secondary antibodies included
donkey anti-goat-FITC (1:200; 705-095-147; Bioconnect) and
donkey anti-rabbit-CY3 (1:2000; 711-165-152; Bioconnect).
UGent11-4-ActA differentiated as EBs in the presence of
BMP4 for 7 days were used as negative controls where only
the secondary antibody was applied.
Western blotting
Whole cell lysates were prepared from second trimester
fetal testis and BMP4-treated EBs (day 7) derived from
UGent11-4-ActA and UGent11-6 hESC lines. Twenty micro
gram proteins from each sample were loaded per lane on a
10% SDS-PAGE gel. Next, proteins were transferred to a
nitrocellulose membrane. Transferred blots were then
blocked in PBT (1· PBS + 0.3% Tween) with 1% BSA for 1 h
at RT followed by incubation in primary antibody (1:500,
rabbit-anti VASA, Cat No. ab13840, Abcam; 1:5000, rabbit-
anti b-TUBULIN, Cat No. ab6046, Abcam) overnight at 4C.
Blots were then washed in PBT thrice for 5 min and incu-
bated in secondary antibody (1:20000, goat-anti-rabbit-HRP,
Cat No. ab6721, Abcam) for 1 h at RT. Blots were again
washed as before, developed using SuperSignal West Dura
Chemiluminescent Substrate (Cat No. 34076; Thermo-
scientific) and were captured using the Bio-Rad VersaDoc
imaging system with Bio-Rad Quantity One software.
RNA isolation and reverse transcription
quantitative polymerase chain reaction
hESCs and EBs from days 3, 7 and 14 were collected and
lysed in 1 mL TRIzol (Cat No. 15596-026; Invitrogen). Total
RNA was purified from the inorganic phase using the
RNeasy Mini Kit (Cat No. 74104; Qiagen). cDNA was
Table 1. Gene Expression Assays Used for
Quantitative Real-Time Polymerase Chain Reaction
QRT-PCR gene expression assays
Genes of interest Assay ID
VASAa Hs00987125_m1
cKITa Hs00174029_m1
OCT4a Hs01895061_u1
NANOGa Hs02387400_g1
NESTINa Hs04187831_g1
PAX6a Hs00240871_m1
HAND1a Hs02330376_s1
PECAM1a Hs00169777_m1
GATA4a Hs00171403_m1
GATA6a Hs00232018_m1
STELLAb 140928
FRAGILISb 122503
SSEA1b 118619
SOX2b 111867
Housekeeping
genes Primer sequences
GAPDH F: AGCCTCAAGATCAGCAATG
R: ATGGACTGTGGTCATGAGTCCTT
B2M F: TGCTGTCTCCATGTTTGATGTATCT
R: TCTCTGCTCCCCACCTCTAAGT
RPL13A F: CCTGGAGGAGAAGAGGAAAGAGA
R: TTGAGGACCTCTGTGTATTTGTCAA
aTaqman gene expression assays.
bRoche real-time ready assays.
qRT-PCR, reverse transcription quantitative polymerase chain
reaction.
IMPACT OF HUMAN EMBRYONIC STEM CELL DERIVATION IN ACTIVIN A 3143
FIG. 1. Pluripotency assays on both Activin A-derived and standard human embryonic stem cell (hESC) lines. (a) Im-
munofluorescence staining for pluripotency markers OCT4 and NANOG, nuclear staining by DAPI and merged images of all
hESC lines when maintained in their undifferentiated state. Scale bar, 50mm. (b) Alkaline phosphatase live staining for all hESC
lines in their undifferentiated state. Scale bar, 50mm. (c) Karyograms for XX hESC lines UGent11-4-ActA, UGent11-5 and
UGent11-6 and XY hESC lines UGent12-3-ActA and UGent11-7. All hESC lines were karyotypically normal. (d) Embryoid body
(EB) differentiation assay of all hESC lines. (i) Gene expression profile of germ layer markers in day 14 EBs. Fold change values
are analyzed compared to OCT4 gene expression in day 14 EBs. For all hESC lines, after 14 days of differentiation as EBs,
ectoderm marker NESTIN and endoderm markers GATA4 and GATA6 upregulated significantly compared to OCT4, P< 0.05;
mesoderm marker HAND1 also showed significant upregulation compared to OCT4, P£ 0.001; (ii) Differentiation of all hESCs
as EBs on day 3, day 7 and day 14. Scale bar, 100mm.
(Continued)
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synthesized using the iScript Advanced cDNA Synthesis Kit
for RT-qPCR (Cat No. 170-8842; Biorad). cDNA concentra-
tion was determined with the Quant-iT Oligreen ssDNA
Assay Kit (Cat No. O11492; Invitrogen) on a Tecan fluores-
cence reader using Magellan software.
Real time polymerase chain reaction (PCR) amplification of
cDNA was performed for VASA, OCT4, cKIT, NANOG
(Taqman Gene Expression Assays; Applied Biosystems),
STELLA, FRAGILIS, SSEA1, SOX2 (Real-time Ready Assays;
Roche). For studying the differentiation of day 14 EBs into the
three germ layers (differentiated in medium without bFGF),
genes analyzed included ectodermal genes NESTIN, PAX6,
mesodermal genes HAND1, PECAM1, endodermal genes
GATA4, GATA6 and pluripotency gene OCT4. The reference
genes were GAPDH, B2M and RPL13A (Table 1). Each
quantitative PCR (qPCR) reaction included 20ml mastermix
and 10 ng cDNA. The mastermix consisted of gene specific
primers and iTAQ supermix with ROX (Cat No. 172-5855;
Biorad) or iTAQ SYBR Green Supermix with ROX (Cat No.
172-5850; Biorad).
The qPCR machine employed was the ABI Prism 7000
Sequence Detection System (Applied Biosystems). The
thermocycling conditions were as follows: 2 min at 95C
followed by 45 cycles of 15 s at 95C followed by 1 min at
60C. All samples were analysed in biological and technical
triplicates. 11-week fetal testis was used as positive control
and no cDNA (water) samples or no RT (RNA) samples
were used as negative controls. Ct values were normalized
FIG. 1. (Continued).
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to the housekeeping genes and the final values were described
as fold change expression values compared to the hESC line
UGent11-7. For EB germ layer gene expression analyses, fold
change expression values were compared to OCT4 expression
in day 14 EBs of each hESC line. Statistical significance was
calculated using t-test and ANOVA on means and standard
deviations of fold change expression values.
Results
hESC lines derived in the presence of Activin A
are pluripotent and show increased propensity
towards PGC differentiation
Based on the fact that mEpiSCs are derived in the presence
of Activin A [27] and have been previously shown to have
high potential to generate PGC-like [24] cells, we also added
Activin A at 20 ng/mL to human embryos at the blastocyst
stage to determine whether this would influence the in vitro
PGC differentiation potential of the derived hESC lines. We
were able to successfully derive two hESC lines in the pres-
ence of Activin A: UGent11-4-ActA (XX) and UGent12-3-
ActA (XY). The other hESC lines UGent11-5 (XX), UGent11-6
(XX) and UGent11-7 (XY) used in this study were all derived
conventionally in the absence of Activin A. All hESC lines
were pluripotent, expressing OCT4 and NANOG (Fig. 1a),
AP positive (Fig. 1b), karyotypically normal (Fig. 1c), and
could be differentiated as EBs expressing markers of the three
germ layers (Fig. 1d). When SB431542, an inhibitor of Activin
A [35], was added at the blastocyst stage, in vitro progression
to the PICMI stage was observed; however, no hESC lines
could be derived (results not shown). This may likely be due
to the fact that SB431542 blocks the TGFb/Activin/Nodal
signaling pathway, which is indispensible to maintain the
primed status of pluripotency in hESCs [36]. Hence, this may
be the probable cause for the successful derivation of hESCs
FIG. 2. Gene expression profiles of all hESC lines upon germ cell-directed differentiation as EBs in the presence of bone
morphogenic protein 4 (BMP4) for early primordial germ cell (PGC) markers STELLA, cKIT, FRAGILIS (a–c), late PGC
marker VASA (d), pluripotency markers OCT4, SOX2, NANOG (e–g), and the differentiation marker SSEA1 (h). Activin A-
derived hESC lines UGent11-4-ActA and UGent12-3-ActA show significantly higher expression for STELLA and cKIT at day
0 and significant upregulation of VASA at day 7, when FRAGILIS is downregulated. For all hESC lines, pluripotency markers
OCT4, SOX2, NANOG were significantly downregulated, and SSEA1 expression increased as differentiation proceeded from
day 0 to day 14. STELLA, cKIT: UGent11-4-ActA (a¢) compared to standard hESC lines at day 0 (a), P £ 0.001; UGent12-3-
ActA (b¢) compared to standard hESC lines at day 0 (b), P £ 0.001; FRAGILIS: Day 7 UGent12-3-ActA EBs (a¢) compared to
day 0 and day 3 EBs (a), P < 0.05; VASA: Day 7 UGent 11-4-ActA EBs (a¢) compared to day 7 EBs of standard hESC lines (a)
P £ 0.001; Day 7 UGent12-3-ActA EBs (b¢) compared to day 7 EBs of standard hESC lines (b) P £ 0.001; OCT4, SOX2, NANOG:
for all hESC lines, differentiation as EBs from day 0 to day 14, P £ 0.001; SSEA1: P < 0.05.
(Continued)
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in the presence of Activin A and failure to generate any hESC
lines upon the inhibition of TGFb/Activin/Nodal signaling
pathway by SB431542; thus, further emphasizing the intricate
nature of the hESC derivation process.
Next, we investigated PGC differentiation potential of
both Activin A-derived hESC lines and standard hESC lines.
At day 0, Activin A-derived hESCs showed significantly
higher STELLA expression compared to standard hESCs (7.4
and 9.2-fold increase for UGent11-4-ActA and UGent12-3-
ActA, respectively; P £ 0.001) (Fig. 2a). The cKIT expression
pattern resembled that of STELLA with high expression
levels in Activin A-derived hESC at day 0 compared to
standard hESCs (Fig. 2b). Hence, these Activin A-derived
hESC lines show high inherent expression levels of early
PGC markers, which may prone them towards germ cell
differentiation. This is further corroborated by the fact that
Activin A-derived hESCs showed significant upregulation of
VASA compared to standard hESCs on day 7 EBs (10 and
7.5-fold increase in UGent11-4-ActA and UGent12-3-ActA,
respectively; P £ 0.001). This upregulation of VASA in dif-
ferentiating Activin A-derived hESCs corresponded to a
downregulation in FRAGILIS expression. From day 7 EBs to
day 14 EBs, expression levels of both FRAGILIS and VASA
were maintained in these differentiating hESCs. In contrast,
standard hESCs showed a steady rise in FRAGILIS expres-
sion from day 0 to day 14 EBs, while VASA continued to be
expressed at a low level (Fig. 2c, d). The pluripotency
markers OCT4, SOX2 and NANOG were significantly
downregulated in all differentiating hESC lines, while SSEA1
continued to rise from day 0 to day 14 EBs (Fig. 2e–h).
As day 7 marked the critical time point for rise in VASA at
the mRNA level in EBs, we immunostained those of the Ac-
tivin A-derived hESC line UGent11-4-ActA and the standard
hESC line UGent11-6 at this time point to check for VASA and
OCT4 presence at the protein level. UGent11-4-ActA showed
higher expression of VASA compared to UGent11-6 (Fig. 3a
and Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/scd). VASA localized to the
nucleus and to the cytoplasm of both dividing and nondi-
viding cells. Very little or no OCT4 expression was seen in day
7 UGent11-4-ActA EBs, while UGent11-6 EBs continued to
show a few OCT4-positive cells with no or very few cells
expressing VASA only in the nucleus (Fig. 3b). It is possible
that these OCT4-positive cells of UGent11-6 represent early
PGCs. These results were further confirmed by western Blot
analysis (Fig. 3c and Supplementary Fig. S2).
50 ng/mL BMP4 is sufficient to direct hESC
differentiation towards PGC-like cells
Various reports have studied the dose dependent effect of
BMP4 in inducing germ cell gene expression in ESCs
FIG. 2. (Continued).
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[2,3,37,38]. In EBs generated from mESCs, a biphasic response
in gene expression was seen upon addition of BMP4 from
20 ng/mL to 500 ng/mL. Here 50 ng/mL, 100 ng/mL and
200 ng/mL showed a gradual increase in early OCT4+ PGC
population, whereas 200 ng/mL led to its decrease and in-
duced mesoderm-directed differentiation [38]. PGC-directed
differentiation of bone marrow mesenchymal stem cells also
showed a BMP4-associated dose dependent increase in VASA
expression where 100 ng/mL proved to be the best concen-
tration compared to 25 ng/mL and 50 ng/mL [37]. A cocktail
of BMPs, including BMP4, BMP7, and BMP8b supplemented
at 100 ng/mL has also proven to be highly beneficial in germ
cell differentiation of hESCs compared to 1 ng/mL and 10 ng/
mL of BMP4 [2]. Thus, we wanted to determine the optimum
concentration of BMP4 for its impact on in vitro PGC differ-
entiation of our Activin A-derived hESC lines. To test this,
UGent11-4-ActA was differentiated as EBs in the absence of
BMP4, and at 10 ng/mL, 50 ng/mL or 100 ng/mL BMP4 up to
day 7. It was observed that 50 ng/mL and 100 ng/mL BMP4
led to significantly higher upregulation of STELLA and VASA
expression as compared to 10 ng/mL BMP4 or its absence.
However, 50 ng/mL and 100 ng/mL concentrations did not
show a significant difference between each other with respect
to their effect on STELLA and VASA expression. Hence,
50 ng/mL BMP4 was employed as a standard dosage in our
experiments. OCT4 expression was unaffected by different
BMP4 concentrations (Fig. 4).
Activin A-derived hESC lines showed high
expression of the endodermal marker GATA-6
in the presence of BMP4 and exhibited active
TGFb/Activin signaling
As the Activin A-derived hESC lines were exposed to
Activin A during their derivation, we wanted to check
whether TGFb/Activin signaling is active during their
differentiation towards PGC-like cells. Translocation of
pSMAD2/3, an active component of TGFb/Activin signal-
ing, from cytoplasm to the nucleus helps in regulating gene
expression [13]. Our immunocytochemistry results showed
that phosphorylated SMAD2/3 is present in day 7 EBs of
UGent11-4-ActA when VASA is upregulated, while it re-
mained absent or at reduced levels in UGent11-6 (Fig. 5a–c).
However, this needs to be further investigated.
As Activin A and BMP4 together are known to induce
differentiation towards the endodermal lineage [39], and to
further emphasize the fact that derivation in Activin A has an
effect on the derived hESC line, we checked whether these
hESC lines were also giving rise to endoderm on day 7 EBs,
while being differentiated in germ cell differentiation media
supplemented with BMP4. We observed GATA-6 positive
cells covering the surface of a large majority of EBs in
UGent11-4-ActA (Fig. 6a), as well as nuclear pSMAD1/5/8
(Fig. 6b) indicative of their responsiveness to BMP4. Hence,
as both pSMAD2/3 and pSMAD1/5/8 are present in dif-
ferentiating Actvin A-derived hESCs, this further confirms
that Activin A-derived hESCs are responsive to both Activin
and BMP signaling upon differentiation, which may explain
their increased potency to differentiate into PGC-like cells.
Discussion
Both mouse EpiLCs [28,29] and mEpiSCs are prone to-
wards germ cell differentiation [24] and are derived in sim-
ilar culture conditions as mostly used for hESC derivation,
except for the extra supplementation of Activin A [27,28]. We
successfully showed that supplementing Activin A during
derivation of hESC lines can generate pluripotent hESCs,
which display predisposition for differentiation towards the
PGC-like lineage. Although Activin A has been shown to
support pluripotency and self-renewal [40] of hESC culture
in feeder-free conditions, derivation of most hESC lines has
been performed in the presence of factors, such as bFGF and
human recombinant leukemia inhibitory factor [41–50]
without Activin A. In 2010, a xeno-free hESC derivation
medium called RegES medium was developed, which con-
tained only 5 ng/mL Activin A. However, this medium was
solely employed to derive hESC lines in xeno-free conditions
for clinical purpose and their lineage-specific differentiation
potential was not compared to standard derived hESC lines
[51,52].
All hESC lines are known to share similar morphology,
growth pattern, and expression of pluripotency markers;
however, variations amongst hESC lines exist at the tran-
scriptional level with culture conditions being one of the
crucial causative factors [45,46,53,54]. For example, differ-
ential expression of 1417 genes was observed upon the cul-
ture of HS237 hESC line in medium with or without serum
[55]. Hence, variations in hESC lines could be a direct result
of the culture environment the embryo was exposed to
during the hESC derivation process. In fact, considerable
changes at the molecular level have been shown during the
process of hESC derivation from blastocyst embryos. These
changes have been highlighted in a study by our group [26],
where a comparative analysis was performed between ICM,
post ICM intermediate (PICMI), and hESCs. It was observed
that as the ICM progresses towards hESCs, the intermediate
PICMI stage is formed, characterized by the expression of
both early and late epiblast markers. Interestingly, germ cell
markers, such as cKIT and FRAGILIS also increased along
with Nodal/Activin signaling during the PICMI stage. These
markers are again downregulated in hESCs although still
higher in expression compared to ICM [26]. Thus, exposing
hESCs during their derivation to 20 ng/mL Activin A,
FIG. 3. Representative immunofluorescence staining of Activin A-derived hESC lines and standard hESC lines for the
pluripotency marker OCT4 and the late PGC marker VASA together with nuclear stain DAPI on day 7 of germ cell-directed
differentiation. (a)Activin A-derived hESC line UGent11-4-ActA showing (i) very low frequency of OCT4-positive cells but a high
number of VASA-positive cells and (ii) VASA localizes to both the nucleus and the cytoplasm (*). Scale bar= (i) 50mm, (ii) 100mm.
(b) Standard hESC line UGent11-6 showing more OCT4-positive cells but no or very low VASA expression in the nucleus and no
cytoplasmic localization. Scale bar= (i) 50mm, (ii) 100mm. (c) Western blot analysis for VASA on second trimester fetal testis,
UGent11-4-ActA and UGent11-6. b-tubulin used as control. (d) Negative control. Scale bar, 50mm.
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similar to mouse EpiLCs and mEpiSCs, boosted their germ
cell differentiation potential unlike the other hESC lines,
which were derived using conventional methods in the ab-
sence of Activin A. On the contrary, we observed that ad-
dition at the blastocyst stage of SB431542, an inhibitor of
Activin A [35], failed to result in hESC lines, further em-
phasizing the unique significance of the hESC derivation
stage.
Germ cell differentiation of hESCs is commonly assessed
by determining expression levels of widely used germ cell
markers, such as STELLA, FRAGILIS, cKIT, SSEA1, and
VASA [56,57]. Our Activin A-derived hESC lines showed
significantly higher base levels of STELLA and cKIT as
compared to standard derived hESC lines. This may indicate
an increased predisposition of these hESC lines towards the
germ cell lineage. Moreover, it was recently reported that
STELLA plays an active role in inducing germ cell directed
differentiation of hESCs [58]. Also, we observed that FRA-
GILIS continued to rise up to day 7 EBs and as it is subse-
quently downregulated, there is a concomitant rise in VASA
expression. Hence, this expression pattern may indicate the
completion of the PGC specification process and that the cells
are in a transition between migratory and premeiotic state.
For the standard hESC lines, early PGC markers, such as
STELLA, FRAGILIS, and cKIT were lowly expressed in the
beginning and their expression rose as differentiation pro-
gresses after BMP4 supplementation with no or very little
expression of VASA. Thus, the conventionally derived hESC
lines without Activin A appear to require longer periods for
the PGC specification process. We also observed a decrease
in the pluripotency markers OCT4, SOX2 and NANOG ac-
companied by a rise in SSEA1 levels indicating that differ-
entiation has occurred successfully in all hESC lines. Higher
expression of VASA was also observed at the protein level in
Activin A-derived hESC lines compared to standard hESC
lines. Although VASA expression is predominantly localized
to the cytoplasm in germ cells, it has also been found in the
cell nucleolus of hESC-derived germ cells as described by
West and colleagues [59]. Similar to these observations, we
also observed both cytoplasmic and nuclear localization of
VASA, which may be indicative for the different time points
of germ cell differentiation. Standard hESC lines failed to
show either of these expression patterns and instead con-
tinued to express Oct4; thus, again pointing to the fact that
these cell lines may still be in the stage of PGC specification
and need extra signals from the environment to continue
their lineage progression into late PGCs.
BMPs are known to play an indispensible role for the
generation and specification of PGCs. As the in vivo PGC-
inducing capacity of BMPs can be extrapolated in vitro,
several studies have used BMP4 as a prerequisite factor for
differentiation of pluripotent stem cells into germ cells
[2,5,8,56]. An important fact is that hESCs respond to
BMP4 in a dose-dependent manner. Kee and colleagues
observed that adding BMP4 at 1 ng/mL, 10 ng/mL and
100 ng/mL corresponded with a significant rise in expres-
sion of VASA [2]. Directed differentiation of bone marrow
mesenchymal stem cells towards germ cells was also ac-
companied by significant upregulation of VASA when the
BMP4 concentration was increased from 25 ng/mL to
100 ng/mL [37]. Similarly, we also observed that BMP4
had a dose-dependent effect on PGC differentiation as
50 ng/mL and 100 ng/mL BMP4 significantly upregulated
FIG. 3. (Continued).
FIG. 4. BMP4 dose-response study on day 7 EBs derived
from the Activin A-derived hESC line UGent11-4-ActA for
the early PGC marker STELLA, the late PGC marker VASA
and the pluripotency marker OCT4. BMP4 is used at
concentrations of 10 ng/mL, 50 ng/mL, and 100 ng/mL.
STELLA: 50 ng/mL BMP4 (a¢) compared to 10 ng/mL BMP4
and –BMP4 (a), P < 0.05; 100 ng/mL BMP4 (b¢) compared to
10 ng/mL and –BMP4 (b¢), P < 0.05. VASA: 50 ng/mL BMP4
(a¢) compared to 10 ng/mL BMP4 and –BMP4 (a), P < 0.05;
100 ng/mL BMP4 (b¢) compared to 10 ng/mL and –BMP4
(b¢), P< 0.05.
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VASA and STELLA expression compared to 10 ng/mL
BMP4 or its absence.
It has been observed in mice that BMP4 interacts with the
ALK2 receptor in visceral endoderm and conditions the
epiblast to form PGCs. In fact, removal of visceral endoderm
completely inhibited the formation of PGCs [60]. During
gastrulation, extraembryonic visceral endoderm is replaced
by definitive endoderm [61] and it has been recently ob-
served that the combination of Activin A and BMP4 results
in approximately 20% increase in the formation of definitive
endoderm when compared to Activin A alone [61]. Upon
differentiation of our Activin A-derived hESCs as EBs in the
presence of BMP4, high expression of the endoderm marker
GATA-6 was observed at the same time point when VASA
was significantly upregulated in our EB cultures (at day 7).
BMP4 and TGFb/Activin signaling were simultaneously
active in Activin A-derived hESCs lines due to nuclear lo-
calization of pSMAD1/5/8 and pSMAD2/3, respectively. In
contrast, no or very low levels of pSMAD2/3 were seen in
standard derived hESC lines.
Thus, as TGFb/Activin signaling plays a role in early cell
fate decision, BMP4 and endoderm development are respon-
sible for PGC induction and formation [14,39,60,62,63]; hence,
the presence of all these factors in our Activin A-derived hESCs
might be responsible for increased differentiation competency
towards the germ cell lineage. Collectively, our results further
reiterate the notion that Activin A induced hESC derivation
helps to generate a pluripotent cell line optimum for studying
in vitro differentiation into the germ cell lineage.
Conclusion
The heterogeneity amongst different hESC lines has a
significant impact on their differentiation potential. We have
FIG. 5. Representative im-
munofluorescence staining of
the TGFb/Activin signaling
pathway mediator pSMAD2/
3 and nuclear stain DAPI on
day 7 BMP4-induced EBs de-
rived from Activin A-derived
hESC lines and standard hESC.
(a) The Activin A-derived
hESC line UGent11-4-ActA
showing phosphorylation and
nuclear localization of
pSMAD2/3 signifying that
Activin signaling is switched
on. Scale bar, 50mm. (b) The
standard hESC line UGent11-6
showing low number of
pSMAD2/3 positive cells
compared to UGent11-4-ActA.
Scale bar, 50mm. (c) Negative
control. Scale bar, 50mm.
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successfully shown that the hESC derivation process has
profound consequences for the subsequent differentiation
potential of the resulting hESC lines. In our study, we have
extrapolated the Activin A containing culture conditions
used for mEpiSC derivation and generation of mouse EpiLCs
to hESC derivation. We were able to show that these Activin
A-derived hESC lines have increased propensity towards
germ cell differentiation compared to standard hESC lines
derived without Activin A. Future research will focus on
detailed analysis and comparison of Activin A-derived hESC
lines at genome-wide transcriptomics and epigenomic level
to standard derived hESC lines and validating the interaction
between Activin signalling and germ cell differentiation in
vitro. We also propose that a differentiation-oriented deri-
vation strategy of hESC lines may hold a crucial key to
success for efficient lineage-specific differentiation.
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